ミグリトール
Based on 3 publication(s) in Google Scholar
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.95%
- CAS 番号: 72432-03-2
- 分子式: C8H17NO5
- 分子量:207.22
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
MedChemExpress（MCE）の使用を引用している文献 Miglitol
MoreAMPK アイソフォーム固有の製品をすべて表示
More
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
1 μM
Compound: 5
|
Inhibition of maltase in human Caco-2 cell model system after 2 hrs
Inhibition of maltase in human Caco-2 cell model system after 2 hrs
|
[PMID: 18595718] |
Miglitol (100-500 μM, 24 h) reduces endothelial cell injury in response to H2O2, exists cytoprotective effects against oxidative stress by H2O2 in bEnd.3 cells[4].
Miglitol (100-500 μM, 0-15 min) activates AMPK and induces eNOS activity and NO production in endothelial cells[4].
Miglitol (100-500 μM, 24 h) inhibits VCAM-1 and ICAM-1 mRNA expression and improves endothelial function in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:bEnd.3 cells
-
Concentration:100-500 μM
-
Incubation Time:24 h
-
Result:Attenuated the bEnd.3 cell injury in response to H2O2, decreased cellular ROS production, reduced DNA injury and the activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP).
-
Cell Line:bEnd.3 cells
-
Concentration:100-500 μM
-
Incubation Time:0-15 min
-
Result:Resulted in time-dependent activation of AMPK, increased Akt phosphorylation (Ser-473) and eNOS phosphorylation (Ser-1177) and activation.
Miglitol (40 mg, mixed in the diet, daily for 29 days) decreases the body weight level, the postprandial plasma glucose level, the levels of plasma glucose and glycoalbumin, and elevates the level of HDL-C in fatty rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OLETF rats[1]
-
Dosage:800 ppm
-
Administration:mixed in the diet, daily for 65 weeks
-
Result:Significantly increased the ΔAUC0-3 h of plasma insulin, HbA1c concentrations and decreased the size of the fibrous area/islets in OLETF rats.
-
Animal Model:Fatty rats[2]
-
Dosage:40 mg
-
Administration:mixed in the diet, daily for 29 days
-
Result:Insignificantly decreased the body weight level on days 15 and 29 and significantly decreased the postprandial plasma glucose level, the levels of plasma glucose and glycoalbumin, and elevated the level of HDL-C in fatty rats.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 72432-03-2
-
性状 Solid
-
分子量 207.22
-
分子式 C8H17NO5
-
Color White to yellow
-
SMILES
O[C@@H]1[C@@H](CO)N(CCO)C[C@H](O)[C@H]1O
-
別名
Miglitol; BAY1099; BAY-m1099
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Asian Nat Prod Res
Biotransformation and activity identification of icariin in human intestinal fungus Pichia occidentalis. [Abstract]2025 May 21:1-12. PMID: 40396926 -
-
溶剤 & 溶解度
H2O : ≥ 200 mg/mL (965.16 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (482.58 mM); Clear solution; Need ultrasonic
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Fukaya, N., et al., The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol, 2009. 624(1-3): p. 51-7. [Content Brief]
[2]. Hirata, A., et al., Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res, 2009. 41(3): p. 213-20. [Content Brief]
[3]. Scott LJ, et al. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000 Mar;59(3):521-49. [Content Brief]
[4]. Aoki C, et al. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. J Pharmacol Sci. 2012;120(2):121-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.8258 mL | 24.1289 mL | 48.2579 mL | 120.6447 mL |
| 5 mM | 0.9652 mL | 4.8258 mL | 9.6516 mL | 24.1289 mL | |
| 10 mM | 0.4826 mL | 2.4129 mL | 4.8258 mL | 12.0645 mL | |
| 15 mM | 0.3217 mL | 1.6086 mL | 3.2172 mL | 8.0430 mL | |
| 20 mM | 0.2413 mL | 1.2064 mL | 2.4129 mL | 6.0322 mL | |
| 25 mM | 0.1930 mL | 0.9652 mL | 1.9303 mL | 4.8258 mL | |
| 30 mM | 0.1609 mL | 0.8043 mL | 1.6086 mL | 4.0215 mL | |
| 40 mM | 0.1206 mL | 0.6032 mL | 1.2064 mL | 3.0161 mL | |
| 50 mM | 0.0965 mL | 0.4826 mL | 0.9652 mL | 2.4129 mL | |
| 60 mM | 0.0804 mL | 0.4021 mL | 0.8043 mL | 2.0107 mL | |
| 80 mM | 0.0603 mL | 0.3016 mL | 0.6032 mL | 1.5081 mL | |
| 100 mM | 0.0483 mL | 0.2413 mL | 0.4826 mL | 1.2064 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Miglitol 関連分類
HY-B0481 関連分類
Powered by Bioz